Hansoh Pharma Reports Positive Phase 2 Results for HS-20089 in Platinum-Resistant Ovarian Cancer

Reuters

10/20

Hansoh Pharma Reports Positive Phase 2 Results for HS-20089 in Platinum-Resistant Ovarian Cancer

Hansoh Pharmaceutical Group Co., Ltd. has announced positive phase 2 clinical trial results for HS-20089, a B7-H4-targeted antibody-drug conjugate $(ADC)$, in patients with platinum-resistant ovarian cancer $(PROC)$. The findings were presented in a poster session at the European Society for Medical Oncology (ESMO) 2025 Annual Meeting and will be featured in an oral presentation at the IGCS 2025 Annual Global Meeting in Cape Town, South Africa. HS-20089 (licensed to GSK as GSK5733584) demonstrated a confirmed objective response rate $(ORR)$ of 48.5%, a duration of response (DoR) of 6.8 months, a median progression-free survival (mPFS) of 6.4 months, and a median overall survival (mOS) of 14.6 months at a dose of 4.8 mg/kg. The safety profile was manageable, consistent with phase 1 data, and no new safety signals were observed. The phase 2 study included heavily pretreated PROC patients regardless of tumor B7-H4 expression. A phase 3 study of HS-20089 is currently ongoing (NCT06855069).

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hansoh Pharmaceutical Group Co. Ltd. published the original content used to generate this news brief on October 20, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2576019002"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2576019002\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2576019002?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-20 08:17","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2576019002","market":"fut","top_or_hot":-1,"title":"Hansoh Pharma Reports Positive Phase 2 Results for HS-20089 in Platinum-Resistant Ovarian Cancer","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Hansoh Pharma Reports Positive Phase 2 Results for HS-20089 in Platinum-Resistant Ovarian Cancer\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Hansoh Pharmaceutical Group Co., Ltd. has announced positive phase 2 clinical trial results for HS-20089, a B7-H4-targeted antibody-drug conjugate <a href=\"https://laohu8.com/S/ADC\">$(ADC)$</a>, in patients with platinum-resistant ovarian cancer <a href=\"https://laohu8.com/S/PROC\">$(PROC)$</a>. The findings were presented in a poster session at the European Society for Medical Oncology (ESMO) 2025 Annual Meeting and will be featured in an oral presentation at the IGCS 2025 Annual Global Meeting in Cape Town, South Africa. HS-20089 (licensed to GSK as GSK5733584) demonstrated a confirmed objective response rate <a href=\"https://laohu8.com/S/ORR\">$(ORR)$</a> of 48.5%, a duration of response (DoR) of 6.8 months, a median progression-free survival (mPFS) of 6.4 months, and a median overall survival (mOS) of 14.6 months at a dose of 4.8 mg/kg. The safety profile was manageable, consistent with phase 1 data, and no new safety signals were observed. The phase 2 study included heavily pretreated PROC patients regardless of tumor B7-H4 expression. A phase 3 study of HS-20089 is currently ongoing (NCT06855069).\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hansoh Pharmaceutical Group Co. Ltd. published the original content used to generate this news brief on October 20, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hansoh Pharma Reports Positive Phase 2 Results for HS-20089 in Platinum-Resistant Ovarian Cancer</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHansoh Pharma Reports Positive Phase 2 Results for HS-20089 in Platinum-Resistant Ovarian Cancer\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-10-20 08:17</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Hansoh Pharma Reports Positive Phase 2 Results for HS-20089 in Platinum-Resistant Ovarian Cancer\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Hansoh Pharmaceutical Group Co., Ltd. has announced positive phase 2 clinical trial results for HS-20089, a B7-H4-targeted antibody-drug conjugate <a href=\"https://laohu8.com/S/ADC\">$(ADC)$</a>, in patients with platinum-resistant ovarian cancer <a href=\"https://laohu8.com/S/PROC\">$(PROC)$</a>. The findings were presented in a poster session at the European Society for Medical Oncology (ESMO) 2025 Annual Meeting and will be featured in an oral presentation at the IGCS 2025 Annual Global Meeting in Cape Town, South Africa. HS-20089 (licensed to GSK as GSK5733584) demonstrated a confirmed objective response rate <a href=\"https://laohu8.com/S/ORR\">$(ORR)$</a> of 48.5%, a duration of response (DoR) of 6.8 months, a median progression-free survival (mPFS) of 6.4 months, and a median overall survival (mOS) of 14.6 months at a dose of 4.8 mg/kg. The safety profile was manageable, consistent with phase 1 data, and no new safety signals were observed. The phase 2 study included heavily pretreated PROC patients regardless of tumor B7-H4 expression. A phase 3 study of HS-20089 is currently ongoing (NCT06855069).\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hansoh Pharmaceutical Group Co. Ltd. published the original content used to generate this news brief on October 20, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1191","symbol_name":"製藥","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251020:nNDLwP66y:1","article_id":"2576019002","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2576019002","pubTimestamp":1760919442,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Hansoh Pharmaceutical Group Co., Ltd. has announced positive phase 2 clinical trial results for HS-20089, a B7-H4-targeted antibody-drug conjugate , in patients with platinum-resistant ovarian cancer . The findings were presented in a poster session at the European Society for Medical Oncology  2025 Annual Meeting and will be featured in an oral presentation at the IGCS 2025 Annual Global Meeting in Cape Town, South Africa. HS-20089  demonstrated a confirmed objective response rate  of 48.5%, a duration of response  of 6.8 months, a median progression-free survival  of 6.4 months, and a median overall survival  of 14.6 months at a dose of 4.8 mg/kg. The safety profile was manageable, consistent with phase 1 data, and no new safety signals were observed. The phase 2 study included heavily pretreated PROC patients regardless of tumor B7-H4 expression. A phase 3 study of HS-20089 is currently ongoing .","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1191":"制药","03692":"翰森制药","BK1583":"高瓴概念","BK1589":"北水核心资产"},"translate_title":"豪森制药报告HS-20089治疗铂类耐药卵巢癌的2期积极结果","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03692":0.9},"content_text":"Hansoh Pharma Reports Positive Phase 2 Results for HS-20089 in Platinum-Resistant Ovarian Cancer\n    \n\n        Hansoh Pharmaceutical Group Co., Ltd. has announced positive phase 2 clinical trial results for HS-20089, a B7-H4-targeted antibody-drug conjugate $(ADC)$, in patients with platinum-resistant ovarian cancer $(PROC)$. The findings were presented in a poster session at the European Society for Medical Oncology (ESMO) 2025 Annual Meeting and will be featured in an oral presentation at the IGCS 2025 Annual Global Meeting in Cape Town, South Africa. HS-20089 (licensed to GSK as GSK5733584) demonstrated a confirmed objective response rate $(ORR)$ of 48.5%, a duration of response (DoR) of 6.8 months, a median progression-free survival (mPFS) of 6.4 months, and a median overall survival (mOS) of 14.6 months at a dose of 4.8 mg/kg. The safety profile was manageable, consistent with phase 1 data, and no new safety signals were observed. The phase 2 study included heavily pretreated PROC patients regardless of tumor B7-H4 expression. A phase 3 study of HS-20089 is currently ongoing (NCT06855069).\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hansoh Pharmaceutical Group Co. Ltd. published the original content used to generate this news brief on October 20, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport,express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}